PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

(2017) Chao Wang et al.   Nature Biomedical Engineering

Extracellular vesicles for drug delivery

(2016) Pieter Vader et al.   ADVANCED DRUG DELIVERY REVIEWS

The Basis of Oncoimmunology

(2016) A. Karolina Palucka et al.   CELL

Biomaterials for enhancing anti-cancer immunity

(2016) Sandeep T Koshy et al.   CURRENT OPINION IN BIOTECHNOLOGY

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

(2016) Lena M. Kranz et al.   NATURE

Designer vaccine nanodiscs for personalized cancer immunotherapy

(2016) Rui Kuai et al.   NATURE MATERIALS

Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

(2016) Axel Hoos   NATURE REVIEWS DRUG DISCOVERY

 -cell-mimetic designer cells provide closed-loop glycemic control

(2016) M. Xie et al.   SCIENCE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

A Facile Approach to Functionalize Cell Membrane-Coated Nanoparticles

(2016) Hao Zhou et al.   Theranostics

Anticancer Platelet-Mimicking Nanovehicles

(2015) Quanyin Hu et al.   ADVANCED MATERIALS

Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy

(2015) Michael S. Goldberg   CELL

Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential

(2015) Padmanee Sharma et al.   CELL

Cell membrane-camouflaged nanoparticles for drug delivery

(2015) Brian T. Luk et al.   JOURNAL OF CONTROLLED RELEASE

Nanoparticle biointerfacing by platelet membrane cloaking

(2015) Che-Ming J. Hu et al.   NATURE

In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity

(2015) Geoffrey M Lynn et al.   NATURE BIOTECHNOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Engineering opportunities in cancer immunotherapy

(2015) Laura Jeanbart et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Virus-mimetic nanovesicles as a versatile antigen-delivery system

(2015) Pengfei Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Cell or Cell Membrane-Based Drug Delivery Systems

(2015) Songwei Tan et al.   Theranostics

Extracellular vesicles as drug delivery systems: Lessons from the liposome field

(2014) Roy van der Meel et al.   JOURNAL OF CONTROLLED RELEASE

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery

(2014) Ronnie H. Fang et al.   NANO LETTERS

Structure-based programming of lymph-node targeting in molecular vaccines

(2014) Haipeng Liu et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Biopolymer implants enhance the efficacy of adoptive T-cell therapy

(2014) Sirkka B Stephan et al.   NATURE BIOTECHNOLOGY

Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy

(2014) Jaeyun Kim et al.   NATURE BIOTECHNOLOGY

A carbon nanotube–polymer composite for T-cell therapy

(2014) Tarek R. Fadel et al.   Nature Nanotechnology

Bioinspired Exosome-Mimetic Nanovesicles for Targeted Delivery of Chemotherapeutics to Malignant Tumors

(2013) Su Chul Jang et al.   ACS Nano

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Re: Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients with Renal Cell Carcinoma

(2012) Samir S. Taneja   JOURNAL OF UROLOGY

Re: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

(2012) Samir S. Taneja   JOURNAL OF UROLOGY

Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy

(2012) Jason Park et al.   NATURE MATERIALS

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform

(2011) C.-M. J. Hu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles

(2010) Matthias T Stephan et al.   NATURE MEDICINE